Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06600542

Inari VISION Registry

Inari VISION Registry — Recruiting • Respiratory / COPD / Asthma • NCT06600542.

📅 09 Apr 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06600542
Start
2025-03-07
Completion
2029-12-31
ClinicaliQ Trial Snapshot
  • Inari VISION Registry — Recruiting • Respiratory / COPD / Asthma • NCT06600542.
  • Global registry tracking safety and performance of Inari Medical devices in routine clinical practice across multiple centers.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This registry is a global prospective, non-randomized, multicenter, observational, active post-market data collection of Inari Medical devices and products. Conditions: Pulmonary Embolism Interventions: Inari Medical Commercially Available Devices Lead Sponsor: Inari Medical Planned Enrollment: 1000 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
GOLD 2025 Report: Global Strategy for Prevention, Diagnosis and Management of COPD
Respiratory / COPD / Asthma · 31 Mar 2026
GOLD 2025 updates COPD diagnosis criteria: spirometry FEV1/FVC
View guideline →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →
Clinical Brief
‘My baby scratches and scratches’: Families say their homes are making their children sick
Respiratory / COPD / Asthma · BBC Health · 23 Apr 2026
Temporary housing conditions are contributing to increased rates of childhood skin conditions (notably atopic dermatitis), with families reporting persistent scratching and distress…
View brief →
Drug Science
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma
Respiratory / COPD / Asthma · 04 Apr 2026
Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma is a clinically relevant Drug Science explainer. Bronchodilation in obstructive airway disease is achieved through…
Explore mechanism →
Guideline
Bronchiectasis (non-CF): Diagnosis and Management (NICE NG117)
Respiratory / COPD / Asthma · 27 Mar 2026
Suspect bronchiectasis in patients presenting with chronic productive cough or recurrent respiratory infections and refer for High-Resolution CT chest imaging; investigate all…
View guideline →
Guideline
Asthma: Diagnosis, Monitoring and Chronic Asthma Management (NICE NG80/BTS)
Respiratory / COPD / Asthma · 25 Mar 2026
Diagnose asthma only with objective evidence of reversible airflow obstruction or bronchial hyperresponsiveness, not on clinical symptoms alone Initiate Step 2 treatment…
View guideline →